Coronavirus News Summary, September 26-October 2

The following are highlights of our free newsletter.Smart and useful science-related information about COVID-19.. Sign up to receive daily newsletter issues in your inbox here..Please consider Monthly donation We support this newsletter.

so Science The magazine Jon Cohen reports on the progress of two companies developing a treatment called monoclonal antibodies for people infected with SARS-CoV-2. On September 29, 2008, Regeneron Pharmaceuticals released initial data from an ongoing placebo-controlled experiment showing that the monoclonal antibody “cocktail” reduced nasal symptoms and viral load in infected patients. .. To perform these treatments, company researchers clone antibodies taken from virus-infected mice or people who have recovered from COVID-19 (for cloning, the genes that make the antibodies are extracted and they are extracted. Includes use in large growth in other rodent cells). An infectious disease researcher and doctor at the University of North Carolina at Chapel Hill called Regeneron’s results “provocative,” a study published two weeks ago by Eli Lilly on an ongoing study of similar antibody treatments against coronavirus. Cohen reports that it reflects. Neither company has published its findings in the journal yet. However, if research goes well, it seems that some doses of these treatments may be available by the end of this year (9/30/20): https://www.sciencemag.org/news/2020/09/provocative-results-boost-hopes-antibody-treatment-covid-19..

More and more medical centers are providing “post-COVID” care to people who have recovered from their illness but are suffering from prolonged problems such as shortness of breath, chest pain, depression and anxiety. Julie Appleby reports so Kaiser Health News (9/30/20). It has been reported that if the start-up costs are overcome, the clinic could boost revenue to the medical center. Outside of such clinics, some COVID-19 survivors are said to have their permanent symptoms imagined, the story says.

Tanya Lewis Scientific American Report on some of the more than 100 US universities that have contracted rapid and frequent SARS-CoV-2 tests on campus for programs offered by the Massachusetts Institute of Technology Broad Institute and Harvard University (9/23/20) .. Educational institutional experience in previous programs has been positive, and an approach to such a test “could be a model for reopening universities across the country.” Lewis writes.. The program allows students, faculty and staff to take tests once or twice a week throughout the semester. The story includes comments from users of the Broad Program, including representatives from Tufts University, Bowdoin College, and the University of Massachusetts Amherst. It is reported here that the basketball arena has been converted into a SARS-CoV-2 test health center.

Adults will be vaccinated against SARS-CoV-2 by next summer, but children may not be vaccinated until the fall of 2021. Karl Zimmer reports for New York Times (9/21/20). The story states that no experiments have begun in the United States to test the safety and efficacy of vaccine candidates in children. According to the story, “Vaccination of children can help reopen society and prevent schools from becoming hotspots for large-scale events.”

Studies show that children are less affected by SARS-CoV-2 than adults. This is because the immune system reacts differently to the virus. Released on September 21, 2008 In the journal Scientific translation medicine, Reported by Apoorva Mandavilli so New York Times (9/25/20). The fast-responding component of the immune system, called the innate immune system, responds strongly to SARS-CoV-2 in children. However, researchers report that the same elements of the immune system are muted in adults. Dr. Michael Mina, a pediatric immunologist at the Harvard Chan Epidemiology Department, said that SARS-CoV-2, like the coronavirus that causes colds, will continue to circulate (become “endemic”) in children over the next few years. It states that the adaptive immune system will develop strongly. The story tells the defense against it, which protects them in adulthood. “We will eventually age from this virus,” the story quotes as he said.

For some vaccine developers, vaccines against SARS-CoV-2 “reduce the risk of mild COVID-19 and meet corporate benchmarks for success, but moderate or severe. It has not been shown to reduce the risk of cases or hospitalization. “According to intensive care hospitalization or death An essay published on September 22, 2008 To New York Times.. This involves vaccines being developed by Moderna, Pfizer, and AstraZeneca. The benchmark must be higher — instead, we need evidence that the vaccine reduces the risk of moderate or severe cases, writes Peter Toshi of the University of Maryland School of Pharmacy and Eric Topol of Scripps Research. The essay states that reducing the risk of mild COVID-19 does not guarantee a similar reduction in moderate or severe cases.

Subscribe to journalist Patrice Peck for a great newsletter on how blacks experience and are affected by the SARS-CoV-2 pandemic. “”Coronavirus News for Blacks.. “

App called “”MITCOVID-19 Indoor Safety GuidelinesAllows users to adjust parameters such as mask usage, ventilation, and room size to estimate the risk of indoor infection of a particular number of SARS-CoV-2 in different types of spaces. This app is based on a mathematical model developed by Martin Z. Bazant and John Bush of the Massachusetts Institute of Technology.

At Apoorva Mandavilli New York Times Please note the above app 9/27/20 Story About the effectiveness of ventilation and air purifiers (sometimes called air purifiers) to reduce SARS-CoV-2 infections, especially in cold weather. Martin Z, co-author of the app. Bazant states that it is best to wear a mask indoors, despite such precautions to protect people from viruses in large buildings. The story also cites a building safety expert at Harvard School of Public Health advising people in buildings and cars to leave windows for ventilation. As for air purifiers and filters, keep the details of MERV and HEPA simple. The story states that “even the most removed devices can help reduce the burden of microorganisms in the air.” According to the University of Arizona epidemiologist Saskia Popesque, quoted in the story, when it comes to UV light, “mainly regulated for its use as a pesticide, its use around people has not been well studied. “. The story advises hiring a professional in the office, school, or at home.

You may enjoy, “Open letter to my lactose intolerant friend about my COVID intolerance, “By Johanna Levene Maxweeney’s (9/30/20).